Identification of phosphotyrosine mimetic inhibitors of human tyrosyl-DNA phosphodiesterase I by a novel AlphaScreen high-throughput assay

Molecular Cancer Therapeutics

Volumn 8, Issue 1, 2009, Pages 240-248

  Marchand, Christophe ^a   Lea, Wendy A ^b   Jadhav, Ajit ^b   Dexheimer, Thomas S ^a   Austin, Christopher P ^b   Inglese, James ^b   Pommier, Yves ^a   Simeonov, Anton ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; METHYL 3,4 DEPHOSTATIN; NF 449; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PHOSPHOTYROSINE; SURAMIN; UNCLASSIFIED DRUG;

ARTICLE; DRUG IDENTIFICATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ASSAY; ENZYME INHIBITION; ENZYME MECHANISM; HIGH THROUGHPUT SCREENING; PRIORITY JOURNAL;

BIOMIMETIC MATERIALS; DRUG EVALUATION, PRECLINICAL; HUMANS; HYDROQUINONES; MOLECULAR STRUCTURE; MUTATION; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PHOSPHOTYROSINE;

EID: 58149486886     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0878     Document Type: Article

References (47)

1. Pommier Y, Redon C, Rao A, et al. Repair of and checkpoint response to topoisomerase I-mediated DNA damage. Mutat Res 2003;532:173-203.
2. Dexheimer TS, Antony S, Marchand C, Pommier Y. Tyrosyl-DNA phosphodiesterase as a target for anticancer therapy. Anticancer Agents Med Chem 2008;8:381-9.
3. Pommier Y, Barcelo JM, Rao VA, et al. In Moldave K, editor. Progress in nucleic acids research and molecular biology. Academic Press; vol. 81. 2006. pp. 179-229.
4. Interthal H, Pouliot JJ, Champoux JJ. The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily. Proc Natl Acad Sci U S A 2001;98:12009-14.
5. Pouliot JJ, Yao KC, Robertson CA, Nash HA. Yeast gene for a Tyr-DNA phosphodiesterase that repairs topo I covalent complexes. Science 1999;286:552-5.
6. Yang S-W, Burgin AB, Huizenga BN, Robertson CA, Yao KC, Nash HA. A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA, type I topoisomerases. Proc Natl Acad Sci U S A 1996;93:11534-9.
7. Plo I, Liao ZY, Barcelo JM, et al. Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. DNA Repair (Amst) 2003;2:1087-100.
8. El-Khamisy SF, Saifi GM, Weinfeld M, et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 2005;434:108-13.
9. Chatterjee S, Cheng M-F, Trivedi D, Petzold SJ, Berger NA. Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines. Cancer Commun 1989;1:389-94.
10. Takashima H, Boerkoel CF, John J, et al. Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy. Nat Genet 2002;32:267-72.
11. Interthal H, Chen HJ, Kehl-Fie TE, Zotzmann J, Leppard JB, Champoux JJ. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J 2005;24:2224-33.
12. Barthelmes HU, Habermeyer M, Christense MO, et al. TDP1 overexpression in human cells counteracts DNA damage mediated by topoisomerases I and II. J Biol Chem 2004;279:55618-25.
13. Nivens MC, Felder T, Galloway AH, Pena MM, Pouliot JJ, Spencer HT. Engineered resistance to camptothecin and antifolates by retroviral coexpression of tyrosyl DNA phosphodiesterase-I and thymidylate synthase. Cancer Chemother Pharmacol 2004;53:107-15.
14. Miao ZH, Agama K, Sordet O, Povirk L, Kohn KW, Pommier Y. Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes. DNA Repair (Amst) 2006;5:1489-94.
15. Zhou T, Lee JW, Tatavarthi H, Lupski JR, Valerie K, Povirk LF. Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1). Nucleic Acids Res 2005;33:289-97.
16. Pouliot JJ, Robertson CA, Nash HA. Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae. Genes Cells 2001;6:677-87.
17. Liu C, Pouliot JJ, Nash HA. Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1. Proc Natl Acad Sci U S A 2002;99:14970-5.
18. Vance JR, Wilson TE. Yeast Tdp1 and Rad1-10 function as redundant pathways for repairing Top1 replicative damage. Proc Natl Acad Sci U S A 2002;99:13669-74.
19. Deng C, Brown JA, You D, Brown JM. Multiple endonucleases function to repair covalent topoisomerase I complexes in Saccharomyces cerevisiae. Genetics 2005;170:591-600.
20. Nitiss KC, Malik M, He X, White SW, Nitiss JL. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage. Proc Natl Acad Sci U S A 2006;103:8953-8.
21. Interthal H, Chen HJ, Champoux JJ. Human Tdp1 cleaves a broad spectrum of substrates including phosphoamide linkages. J Biol Chem 2005;280:36518-28.
22. Inamdar KV, Pouliot JJ, Zhou T, Lees-Miller SP, Rasouli-Nia A, Povirk LF. Conversion of phosphoglycolate to phosphate termini on 3′ overhangs of DNA double-strand breaks by the human tyrosyl-DNA phosphodiesterase hTdp1. J Biol Chem 2002;277:27162-8.
23. Liao Z, Thibaut L, Jobson A, Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol Pharmacol 2006;70:366-72.
24. Davies DR, Interthal H, Champoux JJ, Hol WG. Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. J Mol Biol 2002;324:917-32.
25. Antony S, Marchand C, Stephen AG, et al. Novel high-throughput electrochemiluminescent assay for identification of human tyrosyl-DNA phosphodiesterase (Tdp1) inhibitors and characterization of furamidine (NSC 305831) as an inhibitor of Tdp1. Nucleic Acids Res 2007;35:4474-84.
26. Woodfield G, Cheng C, Shuman S, Burgin AB. Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3′-para-nitrophenyl phosphate ester. Nucleic Acids Res 2000;28:3323-31.
27. Rideout MC, Raymond AC, Burgin AB, Jr. Design and synthesis of fluorescent substrates for human tyrosyl-DNA phosphodiesterase I. Nucleic Acids Res 2004;32:4657-64.
28. Simeonov A, Jadhav A, Thomas C, et al. Fluorescent spectroscopic profiling of compound libraries. J Med Chem 2008;51:2363-71.
29. Ullman EF, Kirakossian H, Switchenko AC, et al. Luminescent oxygen channeling assay (LOCI): sensitive, broadly applicable homogeneous immunoassay method. Clin Chem 1996;42:1518-26.
30. Inglese J, Auld DS, Jadhav A, et al. Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Natl Acad Sci U S A 2006;103:11473-8.
31. Yasgar A, Shinn P, Michael S, et al. Compound management for quantitative high-throughput screening. J Assoc Lab Automat 2008;13:79-89.
32. Niles WD, Coassin PJ. Piezo- and solenoid valve-based liquid dispensing for miniaturized assays. Assay Drug Dev Technol 2005;3:189-202.
33. Cleveland PH, Koutz PJ. Nanoliter dispensing for uHTS using pin tools. Assay Drug Dev Technol 2005;3:213-25.
34. Hill AV. The possible effects of the aggregation of the molecule of haemoglobin on its dissociation curves. J Physiol London 1910;40:4-7.
35. Raymond AC, Staker BL, Burgin AB, Jr. Substrate specificity of tyrosyl-DNA phosphodiesterase I (Tdp1). J Biol Chem 2005;280:22029-35.
36. Feng BY, Simeonov A, Jadhav A, et al. A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 2007;50:2385-90.
37. Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
38. Wu G, Yuan Y, Hodge CN. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J Biomol Screen 2003;8:694-700.
39. Hirano R, Interthal H, Huang C, et al. Spinocerebellar ataxia with axonal neuropathy: consequence of a Tdp1 recessive neomorphic mutation? EMBO J 2007;26:4732-43.
40. Wilson DMI. Processing of nonconventional DNA strand break ends. Environ Mol Mutagen 2007;48:772-82.
41. Debethune L, Kohlhagen G, Grandas A, Pommier Y. Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. Nucleic Acids Res 2002;30:1198-204.
42. Macarron R, Hertzberg RP. Design and implementation of high throughput screening assays. Methods Mol Biol 2002;190:1-29.
43. Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev 1994;20:259-73.
44. Hohenegger M, Waldhoer M, Beindl W, et al. Gsa-selective G protein antagonists. Proc Natl Acad Sci U S A 1998;95:346-51.
45. Hausmann R, Rettinger J, Gerevich Z, et al. The suramin analog 4,4′,4″,4‴-(carbonylbis(imino-5,1,3-benzenetriylbis (carbonylimino)))tetrakis-benzenesulfonic acid (NF110) potently blocks P2X3 receptors: subtype selectivity is determined by location of sulfonic acid groups. Mol Pharmacol 2006;69:2058-67.
46. Imoto M, Kakeya H, Sawa T, et al. Dephostatin, a novel protein tyrosine phosphatase inhibitor produced by Streptomyces. J Antibiotics Tokyo 1993;45:1342-6.
47. Umezawa K. Isolation and biological activities of signal transduction inhibitors from microorganisms and plants. Adv Enzyme Regul 1995;35:43-53.